Martindale Pharma improves Aurum pre-filled syringe packaging

Published: 9-Nov-2011
Packaging Regulatory

To ensure ease of use and improve patient safety

Martindale Pharma, a UK manufacturer and supplier of pharmaceutical specials, has made a number of improvements to its Aurum range of 11 pre-filled syringes.

The Aurum syringes are used for on-the-spot administration of drugs where high visibility and simple drug identification is crucial.

The Brentwood, Essex-based firm has redesigned the range to enhance ease of use and help improve patient safety. Specific improvements include new colour-differentiated packaging; colour-differentiated translucent boxes that confirm contents; and colour-differentiated labels. In addition the firm has improved tamper-evident labels and the packaging is latex-free and Luer Lock fitting.

The firm says its new colour-differentiated packaging meets national and international colour differentiation standards on syringe labelling and also the Royal College of Anaesthetists recommendations on syringe labelling in critical care.

See more

You may also like

Regulatory

BIOSECURE Act on track to curb Chinese biotech investment in the US

Read more
The amended Act was included in the annual defence bill after failing to pass muster in the last key defence spending bill, but has some notable omissions

Trending Articles

  1. UK-US pharma deal removes tariffs and boosts access to innovative medicines The UK has secured a zero-tariff agreement on pharmaceutical exports to the US, alongside major reforms to accelerate NHS access to new treatments
  2. SmartSkin unveils pharma seal assurance solution with real-time insights The breakthrough solution will give manufacturers real-time visibility into container closure integrity and capping performance, with SmartSkin aiming to debut the technology at the upcoming IPSE 4.0 in Barcelona
  3. Ardena strengthens executive leadership with key quality and IT appointments Appointments reflect focus on quality, compliance, and digital integration across global network
  4. Piramal Pharma Solutions’ bioconjugates facility in Grangemouth, UK, receives updated MHRA GMP certificates These certificates cover all activities conducted in the site’s Helix building, including its supporting warehouse and laboratory areas
  5. UK pharma shifts as Merck and AstraZeneca scale back: can CDMOs fill the gap? Recent major site withdrawals and investment pauses have raised concerns about the UK’s industrial strength. But CDMOs say agility, innovation and technical expertise could redefine how and where drugs are made

Upcoming event

From powder to granules: a deep dive into wet granulation methods

14 January 2026 | Virtual See all

You may also like

Regulatory

BIOSECURE Act on track to curb Chinese biotech investment in the US

The amended Act was included in the annual defence bill after failing to pass muster in the last key defence spending bill, but has some notable omissions
Regulatory

One in four European pharma companies at risk of regulatory breaches according to NSF research

The independent survey exposed significant gaps in quality systems, supply chain oversight and data integration, just as EU GMP regulations continue to tighten
Manufacturing

Autopack launches modular semi-automatic bucket line

Flexible system helps manufacturers improve efficiency and reduce costs
Regulatory

NICE raises cost-effectiveness thresholds to boost UK pharma innovation

The UK government has confirmed that NICE will increase its cost-effectiveness thresholds to £25,000-£35,000 per QALY from April 2026, with the aim to support pharmaceutical companies and unlock patient access to new medicines
Manufacturing

A-Z Color advances automated quality control in pharmaceutical label production

EyeC inspection systems help deliver zero-error labels and GMP-compliant reliability
Regulatory

ASTM acquires Insight SQC from Sabine River Partners

ASTM International has announced its acquisition of the Insight SQC platform and its customers through an agreement signed in October 2025
Regulatory

BIA urges new UK access pathway to speed innovative rare disease medicines to NHS patients

The BioIndustry Association (BIA) has called for a connected, flexible UK pathway to improve access to innovative rare disease medicines, as outlined in a new report released in London
Subscribe now